Press releases
- All
2020
November 4, 2020
IRLAB starts Phase IIb/III study with mesdopetam in the US
October 30, 2020
Regulatory
Nomination committee in IRLAB appointed ahead of annual general meeting 2021
October 1, 2020
Regulatory
IRLAB’s mesdopetam IND accepted by the US FDA
September 30, 2020
IRLAB’s shares are now traded on Nasdaq Stockholm Main Market
September 25, 2020
Regulatory
IRLAB publishes prospectus in connection with its listing on Nasdaq Stockholm Main Market
September 23, 2020
Regulatory
IRLAB Therapeutics has been approved for listing on Nasdaq Stockholm Main Market
September 10, 2020
IRLAB’s drug candidate pirepemat featured on cover of top-tier journal JPET
August 26, 2020
Regulatory
IRLAB delårsrapport januari – juni 2020
August 3, 2020
IRLABs IRL752 föreslås få det unika INN-namnet pirepemat av WHO
August 3, 2020
IRLAB’s IRL752 is proposed pirepemat as a unique INN by WHO
July 9, 2020
IRLAB:s kliniska läkemedelskandidat IRL752 publicerad i JPET
July 9, 2020
IRLAB’s clinical drug candidate IRL752 published in JPET
June 24, 2020
IRLAB’s mesdopetam featured on cover of top-tier publication JPET
June 24, 2020
IRLABs mesdopetam presenteras på omslaget av topprankade vetenskapliga tidskriften JPET
June 4, 2020
IRLAB:s Fas IIb/III-studie vid Parkinsons sjukdom inriktas mot god rörelseförmåga
June 4, 2020
IRLAB’s Phase IIb/III study in Parkinson’s disease to target Good ON
May 7, 2020
Regulatory
Kommuniké från årsstämma 2020 i IRLAB Therapeutics AB
May 7, 2020
Regulatory
Report from the Annual General Meeting of IRLAB Therapeutics AB
May 7, 2020
Ordförandens brev till aktieägarna i IRLAB Therapeutics inför årsstämman 2020
May 7, 2020
IRLAB publicerar video av VD-presentationen och förbereder livesändning av årsstämman 2020
May 7, 2020
Regulatory
IRLAB delårsrapport januari – mars 2020
May 6, 2020
IRLAB:s kliniska läkemedelskandidat mesdopetam publicerad i JPET
May 6, 2020
IRLAB’s clinical drug candidate mesdopetam published in JPET
April 24, 2020
IRLAB erbjuder förhandsröstning på årsstämman
April 7, 2020
Regulatory
IRLAB publicerar årsredovisning för 2019
April 7, 2020
Regulatory
IRLAB publishes the annual report for 2019
April 7, 2020
Regulatory
IRLAB kallar till stämma den 7 maj 2020
March 23, 2020
IRLAB:s Fas IIa-studie med IRL752 publiceras i Movement Disorders
March 23, 2020
IRLAB’s Phase IIa study with IRL752 is published in Movement Disorders
February 27, 2020
IRLAB:s företrädesemission övertecknad
February 27, 2020
IRLAB’s rights issue oversubscribed
February 7, 2020
Regulatory
IRLAB offentliggör prospekt avseende företrädesemissionen
February 7, 2020
Regulatory
IRLAB publishes prospectus relating to the rights issue
February 6, 2020
IRLAB lanserar ny webbplats
February 6, 2020
Regulatory
IRLAB bokslutskommuniké 2019
February 4, 2020
IRLAB’s IRL790 receives new name ‘mesdopetam’
February 4, 2020
IRLAB:s IRL790 får nya namnet ’mesdopetam’
2019
December 12, 2019
Regulatory
IRLAB has carried out a directed issue of SEK 70 million and resolves on a rights issue of approximately SEK 145 million
December 12, 2019
Regulatory
IRLAB har genomfört en riktad emission om 70 MSEK och beslutar om företrädesemission om cirka 145 MSEK
December 12, 2019
Regulatory
IRLAB intends to make a capital raise of approximately SEK 215 million
December 12, 2019
Regulatory
IRLAB avser att genomföra en kapitalanskaffning om cirka 215 MSEK
November 7, 2019
Regulatory
IRLAB delårsrapport januari – september 2019
November 6, 2019
IRLAB’s drug candidates IRL942 and IRL1009 have been granted patents in the US and Europe
November 6, 2019
IRLAB:s läkemedelskandidater IRL942 och IRL1009 har beviljats patent i USA och Europa
October 21, 2019
IRLAB is presenting at the Society for Neuroscience 2019 Neuroscience conference
October 21, 2019
IRLAB presenterar vid Society for Neuroscience 2019 års Neuroscience conference
October 17, 2019
Regulatory
Nomination committee in IRLAB appointed
October 17, 2019
Regulatory
Valberedningen i IRLAB utsedd
September 26, 2019
IRLAB’s IRL790 is proposed a unique INN by WHO
September 26, 2019
IRLAB:s IRL790 föreslås få unikt INN av WHO
September 23, 2019
IRLAB presents at the 2019 International Congress of Parkinson’s Disease and Movement Disorders
September 23, 2019
IRLAB presenterar på 2019 års ’International Congress of Parkinson’s Disease and Movement Disorders’
August 28, 2019
Regulatory
IRLAB delårsrapport januari – juni 2019
August 28, 2019
IRLAB to advance clinical development of IRL790 in LIDs based on in-depth analysis of positive Phase IIa results
August 28, 2019
IRLAB fortsätter klinisk utveckling i LIDs med IRL790 baserat på fördjupad analys av positiva Fas IIa-resultat
July 15, 2019
Regulatory
IRLAB reports top line results from Phase IIa study with IRL790
July 15, 2019
Regulatory
IRLAB rapporterar top line-resultat från Fas IIa studie med IRL790
May 28, 2019
IRLAB and research consortium awarded MSEK 2.9 Vinnova grant
May 28, 2019
IRLAB och forskningskonsortium tilldelas Vinnova bidrag på 2,9 MSEK
May 27, 2019
Today, May 27, is the last day of trading in IRLAB’s share before share split
May 27, 2019
Idag, den 27 maj, är sista dag för handel i IRLAB:s aktie före aktiesplit
May 17, 2019
Regulatory
IRLAB announces share split
May 17, 2019
Regulatory
IRLAB genomför aktiesplit
May 9, 2019
IRLAB slutför rekrytering till Fas II-studien med IRL790 för Parkinsons sjukdomspatienter med dyskinesi
April 25, 2019
Regulatory
IRLAB – Resolutions at Annual General Meeting 2019
April 25, 2019
Regulatory
IRLAB – beslut vid årsstämma 2019
April 25, 2019
Regulatory
IRLAB delårsrapport januari-mars 2019
April 3, 2019
Regulatory
IRLAB Therapeutics AB publishes annual report for 2018
April 3, 2019
Regulatory
IRLAB Therapeutics AB publicerar årsredovisning för 2018
March 26, 2019
Regulatory
IRLAB Therapeutics AB kallar till årsstämma den 25 april 2019
March 14, 2019
IRLAB adds sites to Phase II study with IRL790 and passes DSMB’s second safety review
March 14, 2019
IRLAB adderar kliniker till Fas II-studie med IRL790 och passerar DSMB:s andra säkerhetsgranskning
February 27, 2019
Regulatory
IRLAB bokslutskommuniké 2018
2018
December 18, 2018
IRLAB provides update on drug candidate IRL790’s clinical program
December 18, 2018
IRLAB uppdaterar om läkemedelskandidaten IRL790s kliniska program
December 6, 2018
Nature’s npj Parkinson’s Disease publishes clinical study with IRLAB’s drug candidate IRL790
December 6, 2018
Natures npj Parkinson’s Disease publicerar klinisk studie med IRLAB:s läkemedelskandidat IRL790
November 22, 2018
A new patent application for IRLAB’s drug candidate IRL752 has been published by World Intellectual Property Organization, WIPO
November 22, 2018
En ny patentansökan för IRLAB:s läkemedelskandidat IRL752 har publicerats av World Intellectual Property Organization, WIPO
November 14, 2018
Regulatory
IRLAB delårsrapport januari – september 2018
October 30, 2018
IRLAB provides in-depth information on results from successful Phase IIa study with IRL752 in Parkinson’s disease
October 30, 2018
IRLAB lämnar fördjupad information om resultat från framgångsrik Fas IIa-studie med IRL752 i Parkinsons sjukdom
September 26, 2018
IRLAB presents ISP at the CNS and Neurodegenerative Targets conference in Boston
September 26, 2018
IRLAB presenterar ISP vid konferensen CNS and Neurodegenerative Targets i Boston
September 20, 2018
Regulatory
Nomination committee appointed in IRLAB
September 20, 2018
Regulatory
Valberedningen i IRLAB utsedd
September 19, 2018
Regulatory
IRLAB nominates two new candidate drugs and updates the pipeline
September 19, 2018
Regulatory
IRLAB utser två nya läkemedelskandidater och uppdaterar projektportföljen
September 11, 2018
IRLAB Receives Notice of Allowance for U.S. Patent
September 11, 2018
IRLAB har erhållit notice of allowance för amerikanskt patent
August 30, 2018
Regulatory
IRLAB reports promising efficacy data from Phase IIa-study with IRL752
August 30, 2018
Regulatory
IRLAB rapporterar lovande effektdata från Fas IIa-studie med IRL752
August 29, 2018
Regulatory
IRLAB delårsrapport januari – juni 2018
June 29, 2018
Regulatory
IRLAB reports top-line results from Phase IIa study with IRL752
June 29, 2018
Regulatory
IRLAB rapporterar ”top-line” resultat från Fas IIa studie med IRL752
May 23, 2018
Regulatory
IRLAB Therapeutics has raised SEK 138.6 million in a directed share issue to top tier investors in the US and Sweden
May 23, 2018
Regulatory
IRLAB Therapeutics har genomfört en riktad nyemission om 138,6 mkr till topprankade investerare i USA och Sverige
May 17, 2018
Regulatory
IRLAB prepares for listing on the Nasdaq Stockholm main market
May 17, 2018
Regulatory
IRLAB förbereder notering på Nasdaq Stockholms huvudlista
May 16, 2018
Regulatory
IRLAB – Resolutions at Annual General Meeting 2018
May 16, 2018
Regulatory
IRLAB – Beslut vid årsstämma 2018
May 16, 2018
Regulatory
IRLAB delårsrapport januari – mars 2018
April 20, 2018
Regulatory
IRLAB Therapeutics AB (publ) publicerar årsredovisning 2017
April 13, 2018
Regulatory
IRLAB Therapeutics AB (publ) kallar till årsstämma den 16 maj 2018
March 12, 2018
International attention on IRLAB’s discovery platform
March 12, 2018
Internationell uppmärksamhet för IRLAB:s forskningsplattform
February 27, 2018
Regulatory
IRLAB Bokslutskommuniké 2017
January 31, 2018
IRLAB update on clinical Phase II pipeline – IRL752 and IRL790
January 31, 2018
IRLAB uppdaterar om pipeline i klinisk fas – mycket goda förutsättningar för fortsatt utveckling av båda läkemedelskandidaterna, IRL752 och IRL790
2017
November 15, 2017
Regulatory
IRLAB receives MHRA approval to conduct Phase II trials with IRL790 in Britain
November 15, 2017
Regulatory
IRLAB får tillstånd att genomföra Fas II-studie med IRL790 i Storbritannien
November 15, 2017
Regulatory
IRLAB delårsrapport januari – september 2017
October 5, 2017
Regulatory
IRLAB receives approval from the Finnish MPA (Fimea)
October 5, 2017
Regulatory
IRLAB erhåller tillstånd från finska läkemedelsverket
October 4, 2017
IRLAB starts Phase II study with IRL752 for the treatment of Parkinson’s disease dementia
October 4, 2017
IRLAB inleder Fas II-studie med IRL752 för behandling av demens vid Parkinsons sjukdom
September 20, 2017
Regulatory
Nomination committee appointed in IRLAB
September 20, 2017
Regulatory
Valberedningen i IRLAB utsedd
August 29, 2017
Regulatory
IRLAB delårsrapport april-juni 2017
August 25, 2017
Regulatory
IRLAB receives approval to initiate Phase II trials with IRL752
August 25, 2017
Regulatory
IRLAB erhåller tillstånd att genomföra Fas II-studie med IRL752
August 17, 2017
IRLAB signs agreement with TCTC to conduct Phase-2 study with IRL790
August 17, 2017
Regulatory
IRLAB signs agreement with TCTC to conduct Phase-2 study with IRL790
August 17, 2017
Regulatory
IRLAB tecknar avtal om Fas 2-studie med IRL790
June 30, 2017
Regulatory
IRLAB utser ny CFO och rekryterar forskare
May 24, 2017
Regulatory
IRLAB patentansöker om storskalig produktionsmetod
May 16, 2017
Regulatory
IRLAB – Beslut vid årsstämma 2017
May 16, 2017
Regulatory
IRLAB Therapeutics delårsrapport jan-mars 2017
May 15, 2017
Regulatory
IRLAB meddelar positiva resultat från studie med IRL790
April 24, 2017
Regulatory
Valberedningens förslag till styrelse i IRLAB Therapeutics AB
April 10, 2017
Regulatory
IRLAB Therapeutics AB (publ) publicerar årsredovisning för 2016
April 10, 2017
Regulatory
IRLAB Therapeutics AB (publ) kallar till årsstämma den 16 maj 2017
March 16, 2017
Regulatory
IRLAB Therapeutics AB (publ) rapporterar positiva resultat från kliniska Fas 1-studier för IRL752 och ingår avtal om att genomföra Fas 2-studier
February 28, 2017
Första handelsdag för IRLAB Therapeutics aktier på First North Premier
February 27, 2017
Regulatory
IRLAB Therapeutics AB (publ) Bokslutskommuniké för 2016
February 14, 2017
IRLAB Therapeutics offentliggör utfall i nyemission – första handelsdag planerad till 28 februari
February 10, 2017
IRLAB Therapeutics AB:s (publ) har godkänts för notering på First North Premier
January 30, 2017
IRLAB Therapeutics inleder teckningsperiod för nyemission inför listning på Nasdaq First North Premier
January 25, 2017
IRLAB Therapeutics ansöker om listning på Nasdaq First North Premier och offentliggör prospekt
January 24, 2017
IRL’s drug discovery platform, the Integrative Screening Process (ISP), and an application, has been published in ACS Chemical Neuroscience
2016
October 13, 2016
IRL receives MPA approval to conduct a 4 week Phase Ib clinical study with IRL790 in patients with Parkinsons disease
February 3, 2016
IRL receives MPA approval and initiates Phase I trials with IRL752, its second compound reaching clinical development
2015
December 14, 2015
IRL receives SEK 4.98 million from Vinnova for Phase I studies with IRL790
October 30, 2015
IRL receives MPA approval to conduct Phase I trials with IRL790, a novel treatment for complications in Parkinson’s disease
October 9, 2015
IRL scientists lead investigation of long term clinical effects of widely prescribed medications in neurodegenerative disorders
May 25, 2015
IRL files new patent application
May 25, 2015
Highly experienced pharma executives join IRL’s Board of Directors
2014
October 21, 2014
IRL secures additional financing
June 23, 2014
IRL receives SEK 3.8 million from VINNOVA